SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Letter to the Editor

Split Viewer

Blood Res 2016; 51(1):

Published online March 31, 2016

https://doi.org/10.5045/br.2016.51.1.61

© The Korean Society of Hematology

A case of Pneumocystis jiroveci pneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma

Jeonghoon Ha*, Yunhwa Jung, Yunduk Jung, Sanbin Lee, Yoonseo Lee, and Insook Woo

Author Info. +

Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Correspondence to : Jeonghoon Ha. Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, 10, 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea. hajhoon@catholic.ac.kr

Received: February 17, 2015; Revised: March 27, 2015; Accepted: April 20, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

FIGURES

Go to
Fig. 1.

A chest X-ray showed consolidation in right lower lung field (A). Followed-up chest X-ray which was performed 10 days after TMP-SMX treatment showed interval regression of consolidation in right lung field (B).


Fig. 2.

A chest computed tomography (CT) scan revealed newly noted diffuse and multifocal patchy ground glass opacity and consolidation in both lungs (right side predominant).


TABLES

Go to
Table. 1.

Table 1 Clinical characteristics of 5 cases of Pneumocystis jiroveci pneumonia during bendamustine-containing chemotherapy.

Abbreviations: DLBCL, Diffuse large B-cell lymphoma; TMP-SMX, trimethoprim-sulfamethoxazole; R-COP, rituximab, cyclophosphamide, vincristine, prednisolone; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone; ALC, absolute lymphocyte count; PJP, Pneumocystis jiroveci pneumonia.

REFERENCES

Go to
  1. Obeid, KM, Aguilar, J, Szpunar, S, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk, 2012;12;66-69.
    Pubmed
  2. Green, H, Paul, M, Vidal, L, Leibovici, L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc, 2007;82;1052-1059.
    Pubmed
  3. Kurokawa, T, Kaya, H, Yoshida, T. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J Clin Exp Hematop, 2010;50;159-162.
    Pubmed
  4. Cheson, BD, Friedberg, JW, Kahl, BS, Van der Jagt, RH, Tremmel, L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk, 2010;10;452-457.
    Pubmed
  5. Kahl, BS, Bartlett, NL, Leonard, JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer, 2010;116;106-114.
    Pubmed
  6. Klippstein, A, Schneider, CP, Sayer, HG, Höffken, K. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol, 2003;129;316-319.
    Pubmed
  7. Carter, SJ, Bernstein, SH, Friedberg, JW, Barr, PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res, 2011;35;e223-e224.
    Pubmed
  8. Reinbolt, RE, Alam, S, Layman, R, Shapiro, C, Lustberg, M. Pneumocystis jiroveci pneumonia in an atypical Host. Clin Breast Cancer, 2012;12;138-141.
    Pubmed
  9. Hosoda, T, Yokoyama, A, Yoneda, M, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma, 2013;54;1327-1328.
    Pubmed
  10. Ito, K, Okamoto, M, Ando, M, et al. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma, 2015;56;1123-1125.
    Pubmed
  11. Brugger, W, Ghielmini, M. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist, 2013;18;954-964.
    Pubmed

Article

Letter to the Editor

Blood Res 2016; 51(1): 61-63

Published online March 31, 2016 https://doi.org/10.5045/br.2016.51.1.61

Copyright © The Korean Society of Hematology.

A case of Pneumocystis jiroveci pneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma

Jeonghoon Ha*, Yunhwa Jung, Yunduk Jung, Sanbin Lee, Yoonseo Lee, and Insook Woo

Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Correspondence to: Jeonghoon Ha. Division of Hematology-Oncology, Department of Internal Medicine, Yeouido St Mary's Hospital, 10, 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea. hajhoon@catholic.ac.kr

Received: February 17, 2015; Revised: March 27, 2015; Accepted: April 20, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Fig 1.

    Download
    Figure 1.

    A chest X-ray showed consolidation in right lower lung field (A). Followed-up chest X-ray which was performed 10 days after TMP-SMX treatment showed interval regression of consolidation in right lung field (B).

    Blood Research 2016; 51: 61-63https://doi.org/10.5045/br.2016.51.1.61

    Fig 2.

    Download
    Figure 2.

    A chest computed tomography (CT) scan revealed newly noted diffuse and multifocal patchy ground glass opacity and consolidation in both lungs (right side predominant).

    Blood Research 2016; 51: 61-63https://doi.org/10.5045/br.2016.51.1.61

    Table 1 . Clinical characteristics of 5 cases of Pneumocystis jiroveci pneumonia during bendamustine-containing chemotherapy..

    Abbreviations: DLBCL, Diffuse large B-cell lymphoma; TMP-SMX, trimethoprim-sulfamethoxazole; R-COP, rituximab, cyclophosphamide, vincristine, prednisolone; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone; ALC, absolute lymphocyte count; PJP, Pneumocystis jiroveci pneumonia..

    References

    1. Obeid, KM, Aguilar, J, Szpunar, S, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk, 2012;12;66-69.
      Pubmed
    2. Green, H, Paul, M, Vidal, L, Leibovici, L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc, 2007;82;1052-1059.
      Pubmed
    3. Kurokawa, T, Kaya, H, Yoshida, T. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J Clin Exp Hematop, 2010;50;159-162.
      Pubmed
    4. Cheson, BD, Friedberg, JW, Kahl, BS, Van der Jagt, RH, Tremmel, L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk, 2010;10;452-457.
      Pubmed
    5. Kahl, BS, Bartlett, NL, Leonard, JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer, 2010;116;106-114.
      Pubmed
    6. Klippstein, A, Schneider, CP, Sayer, HG, Höffken, K. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol, 2003;129;316-319.
      Pubmed
    7. Carter, SJ, Bernstein, SH, Friedberg, JW, Barr, PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res, 2011;35;e223-e224.
      Pubmed
    8. Reinbolt, RE, Alam, S, Layman, R, Shapiro, C, Lustberg, M. Pneumocystis jiroveci pneumonia in an atypical Host. Clin Breast Cancer, 2012;12;138-141.
      Pubmed
    9. Hosoda, T, Yokoyama, A, Yoneda, M, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma, 2013;54;1327-1328.
      Pubmed
    10. Ito, K, Okamoto, M, Ando, M, et al. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma, 2015;56;1123-1125.
      Pubmed
    11. Brugger, W, Ghielmini, M. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist, 2013;18;954-964.
      Pubmed
    Blood Res
    Volume 59 2024
    Current Issue Archives

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download